Skip to main content
Erschienen in: Supportive Care in Cancer 12/2013

Open Access 01.12.2013 | Letter to the editor

Reply to Molassiotis

verfasst von: Edzard Ernst, Paul Posadzki

Erschienen in: Supportive Care in Cancer | Ausgabe 12/2013

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Molassiotis is the author of about 40 reviews, all of which are prone to the shortcomings he highlights. His statement, “I urge researchers in the field not to proliferate publications of ‘systematic’ reviews of a very small number and of admittedly poor/low quality level trials”, is thus surprising to say the least. The main point of his response seems to be that “systematic reviews of few and low-quality studies do not help anybody”. We feel that such articles can still be useful, for instance, for disclosing important deficits in our current knowledge.
In making this point, Molassiotis seems to display a lack of understanding of science in general and systematic reviews in particular. Here are a few of his most obvious errors:
He asks “didn’t we know this [the result of a systematic review] before the review”? It seems obvious to us that the findings of a review can never be known before the research has been conducted.
He refers to “systematic reviews on the same topic by several different authors”. Yet a closer look at the actual articles he quotes informs us that they are, in fact, on subtly different subjects.
He claims that we believe that “anything that does not have a sham arm is not a good trial”. Yet we never stated anything like this. We would, however, argue that, for determining whether an intervention has therapeutic effects beyond placebo, a placebo/sham control is helpful.
He argues that controlling for placebo effects in acupuncture trials is done “to give some ‘science’ credentials to such trials and mimic drug trial placebo-controlled designs”. We would counter that the sole reason for doing this is to be able to differentiate between specific and non-specific therapeutic effects; in our view, this is important for determining the value of any treatment.
He states, “I am questioning the ethics” [of such sham-controlled studies]. We would insist that differentiating between placebo and specific effects is a crucial ethical task of clinical research.
He claims that “bringing all acupuncture trials together as one treatment is like mixing apples and oranges”. We would like to remind him that, by definition, systematic reviews are about summary judgements of this nature and that most of his own reviews have followed exactly the same principles.
Finally, we agree with him that “we should not deny patients the possibility of experiencing symptom relief and health improvements because of sterile and incapacitating arguments about how to carry out ‘proper’ acupuncture trials”. But we need to point out that, before we can be sure that patients do benefit from our interventions, we need to determine whether they generate more good than harm. In our opinion, this requires rigorous research, and any attempt to bypass this process is likely to be counterproductive and unethical.

Conflict of interest

Both authors declare no competing interests.
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
download
DOWNLOAD
print
DRUCKEN

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Metadaten
Titel
Reply to Molassiotis
verfasst von
Edzard Ernst
Paul Posadzki
Publikationsdatum
01.12.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 12/2013
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-1990-5

Weitere Artikel der Ausgabe 12/2013

Supportive Care in Cancer 12/2013 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.